Navigation Links
InVitria Reveals Technology to Optimize Hybridoma Production Performance
Date:4/22/2009

Article in Spring edition of Bioprocessing Journal reports InVitria's recombinant human serum albumin (Cellastim) and recombinant lactoferrin (Lacromin) cell culture supplements optimize cell growth and productivity in hybridoma cells.

Fort Collins, CO (PRWEB) April 22, 2009-- Recent studies using both classical media and the leading commercial serum-free hybridoma media formulations proved that InVitria's cell culture supplements optimized cell growth and productivity of hybridoma cells.1 Further, the studies revealed that Cellastim supports cell adaptation and survival in chemically-defined media.

Additional findings from the study showed that Cellastim improved the cell growth and productivity in long-term culture. In a 25-day period, cell doublings in Cellastim-supplemented media were twice that of media without Cellastim. Also, antibody production was 65% higher in the commercial media with Cellastim while cells supplemented with Cellastim grew to higher density than those in unsupplemented media.

"This research incorporated classical media as well as several leading commercial media available on the market," said Dr. Steve Pettit, the project's lead researcher. "We achieved optimal cell density and quicker doubling times as well as better cell productivity when Cellastim was added to these media. We also reported that Lacromin improves hybridoma cell culture performance."

Lacromin increased cell density in supplemented media nearly double compared to that of media without Lacromin supplementation. A significant increase in antibody production was recognized in all Lacromin-treated media, exceeding the level achieved with 5% fetal bovine serum (FBS).

"This research supports what customers have been reporting from their use of Cellastim and Lacromin for hybridoma cell culture," said InVitria President and CEO Scott Deeter. "Cellastim has been shown to not only optimize hybridoma performance, but also outperform other sources of native and recombinant albumin."

To obtain a copy of the above-mentioned article entitled, "Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin," please contact InVitria at info(at)InVitria(dot)com or 1-800-916-8311.

About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research and diagnostics.

1Pettit S, Santos M, Tanner T, Huang N. Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin. BioProcessing Journal 2009; 8(1): 50-55.

###

Read the full story at http://www.prweb.com/releases/hybridomacells/hybridomaproduction/prweb2350604.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. InVitria Headlines Sponsorship of WilBio's Waterside Conference
2. InVitria Announces Launch of Recombinant Albumin for Diagnostics
3. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
4. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
5. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
6. InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting
7. InVitria to Present at WilBio's International Cell Engineering Meeting
8. Retirement Living TV Reveals: Sex Is The Real Fountain of Youth
9. New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies
10. New Research Reveals Need for Doctors to Know About Medical Tattoos
11. Study Reveals How Salmonella Hijacks Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy ... societal issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... for causes around the world. , Running for charity has become a ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ ... #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with God. ... with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “The Adventures of ... smart and silly dog who lives his life to the fullest, as God intended. ... published author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially ...
(Date:3/23/2017)... Alexandria, Virginia (PRWEB) , ... March 23, 2017 ... ... quality public health services to their communities, 16 more public health departments have ... This week’s decisions bring another 4.5 million people into the expanding network of ...
(Date:3/23/2017)... ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the contributions of those ... a significant impact on the careers of all others involved. , On Monday, ... into the MBI’s Hall of Fame. The induction took place during the World of ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017  Zymo Research Corp., also known ... Inc., who designs, manufactures and distributes liquid ... teams Zymo Research,s DNA methylation detection and ... products with Hamilton,s high-throughput automation platforms. Zymo ... microbiomics and RNA isolation for use on ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... A ReportsnReports.com report says, over the recent years, global ... sales of Adcetris and Kadcyla have been witnessing rapid growth after ... is driven by large number of ADC drugs in pipeline, rise ... ADCs. ... Tables and 94 Figures, 10 Major Company Profiles, spread across 154 ...
Breaking Medicine Technology: